SCHEMBL1486536

SCHEMBL1486536

CCCCc1nc2c[n+]([O-])c3ccc(OCc4ccccc4)cc3c2n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
MAOB P27338 1/20 0.39
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
IP6K1 Q92551 1/20 0.38
AS3MT Q9HBK9 1/20 0.37
SRD5A2 P31213 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
CYP3A4 P08684 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1486602 0.91 TLR7 (0.37) PDE4APDE4BPDE4CPDE4DMAOB
SCHEMBL1486681 0.91 MAOB (0.39) PDE4APDE4BPDE4CPDE4DMAOB
SCHEMBL1486543 0.90 MEN1 (0.44) MEN1NPC1RAB9AKMT2AMAOB
SCHEMBL1486545 0.89 RAB9A (0.41) MEN1NPC1RAB9AKMT2AMAOB
SCHEMBL1486784 0.88 PSEN1 (0.38) MEN1KMT2APDE4APDE4BPDE4C
SCHEMBL1486502 0.88 MAOB (0.36) MAOBCYP3A4ALDH1A1KDM4E
SCHEMBL1486562 0.83 RAB9A (0.40) MEN1NPC1RAB9AKMT2AMAOB
SCHEMBL1486561 0.82 IP6K1 (0.45) MEN1NPC1RAB9AKMT2APDE4A
SCHEMBL1960376 0.80 SMN1; SMN2 (0.44) MEN1KMT2APDE4APDE4BPDE4C
SCHEMBL1486524 0.77 TLR7 (0.40) MEN1NPC1RAB9AKMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658076-B1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2013-03-06 EP disclosed
US-8263594-B2 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-09-11 US disclosed
US-20110144099-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2011-06-16 US disclosed
US-7897597-B2 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
EP-1658076-A4 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2009-02-25 EP disclosed
US-20090018122-A1 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2009-01-15 US disclosed
EP-1658076-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2006-05-24 EP disclosed
WO-2005020999-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018122-A1 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines IL2, IFNG, IRF3 MEN1 4690/4885NPC1 2265/4885RAB9A 1595/4885
US-20110144099-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 MEN1 4631/4885NPC1 2205/4885RAB9A 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.